共 50 条
- [1] SGNLVA-005: Open-label, phase 2 study of ladiratuzumab vedotin (LV) for aerodigestive tract malignanciesANNALS OF ONCOLOGY, 2020, 31 : S164 - S165Guthrie, T.Gabrail, N.Sher, A.Bruce, J.Sanborn, R.Lee, A.Graham, R.Tafur, I.Pippas, A.Wang, Y.Wang, Z.Anderson, I.
- [2] Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)Sher, Amna FalakBruce, Justine YangOh, Sung YongAnderson, Ian ChurchillOh, Do-YounNott, Louise M.Lee, Jong-SeokLin, Chia-ChiMehra, RaneeShim, Byoung YongSu, Wu-ChouGuthrie, Troy H.Gabrail, Nashat Y.Sanborn, Rachel E.Lee, Arielle ShebayCortinovis, Diego LuigiSwiecicki, PaulWang YinghuiWang ZejingCho, Jae Yong
- [3] Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)Sher, Amna FalakBruce, Justine YangGabrail, Nashat Y.Anderson, Ian ChurchillPatrikidou, AnnaSanborn, Rachel E.Cho, Jae YongLee, Arielle ShebayLee, Jong-SeokNott, Louise M.Oh, Do-YounOh, Sang CheulOh, Sung YongWang YinghuiWang ZejingGuthrie, Troy H.
- [4] Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumorsANNALS OF ONCOLOGY, 2021, 32 : S671 - S672Arkenau, H-T.Guthrie, T.Mekhail, T.Cortinovis, D.Antonuzzo, L.Bruce, J. Y.Gabrail, N.Anderson, I.Oh, S. C.Oh, S. Y.Nott, L.Shah, M. A.Sanborn, R. E.Oh, D-Y.Cho, J. Y.Lin, C-C.Lee, A.Wang, Y.Wang, Z.Sher, A.
- [5] SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancerANNALS OF ONCOLOGY, 2020, 31 : S393 - S393Cortes, J.Diab, S.Basho, R. K.Oliveira, M.Pluard, T.Alemany, C.Brown-Glaberman, U.Meisel, J.Boni, V.Sinha, R.Garcia Estevez, L.Ettl, J.Kuemmel, S.Manso Sanchez, L. M.Moon, Y. W.Villanueva Vazquez, R.Wuerstlein, R.Wang, Y.Wang, Z.Han, H.
- [6] SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancerANNALS OF ONCOLOGY, 2019, 30Boni, V.Alemany, C.Meisel, J. L.Sinha, R.Sterrenberg, D.Tkaczuk, K. H. R.Wang, Y.Wang, Z.Han, H. S.
- [7] SGNLVA-002: Single-arm, open label phase lb/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Han, Hyo S.Alemany, Carlos A.Brown-Glaberman, Ursa AbigailPluard, Timothy J.Sinha, RajniSterrenberg, DanielleAlbain, Kathy S.Basho, Reva K.Biggs, DavidBoni, ValentinaDiab, SamiTsai, Michaela L.Tkaczuk, Katherine HannaWang, YinghuiWang, ZejingMeisel, Jane Lowe
- [8] Phase II open-label study of sunitinib in patients with advanced breast cancerBreast Cancer Research and Treatment, 2012, 136 : 759 - 767Denise A. YardleyE. Claire DeesStephen D. MyersSherry LiPaul HealeyZhixiao WangMarla J. BrickmanJolanda PaoliniKenneth A. KernDennis L. Citrin
- [9] Phase II open-label study of sunitinib in patients with advanced breast cancerBREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767Yardley, Denise A.Dees, E. ClaireMyers, Stephen D.Li, SherryHealey, PaulWang, ZhixiaoBrickman, Marla J.Paolini, JolandaKern, Kenneth A.Citrin, Dennis L.
- [10] A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS719 - TPS719Kasi, AnupPhadnis, Milind A.Al-Rajabi, Raed Moh'd TaiseerBaranda, Joaquina CelebreLi, HaoranCarroll, ErinBelcher, CatheyBradbury, ShannonCollins, ZacharySun, Weijing